Dysregulated Expression of Protein Kinase CK2 in Renal Cancer

Roelants, Caroline; Giacosa, Sofía; Duchemin-Pelletier, Eve; McLeer-Florin, Anne; Tisseyre, Céline; Aubert, C.; Champelovier, Pierre; Boutonnât, Jean; Descotes, J; Rambeaud, Jean‐Jacques; Arnoux, V.; Long, Jean-Alexandre; Pasquier, Dominique; Laramas, Mathieu; Kassem, Maysoun; David-Boudet, Laurence; Schoutteten, Laure; Bestgen, Benoît; Pillet, Catherine; Cochet, Claude; Filhol, Odile

doi:10.1007/978-3-319-14544-0_14

Cited by 13 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different reports have shown a link between the expression of CK2 catalytic subunits (CK2α/α’) and diverse types of carcinomas [ 26 – 32 , 49 , 50 ], The results of our study agree with an increase in nuclear CK2 catalytic subunits content in ccRCC, as previously reported in other human cancers [ 27 , 28 , 32 , 49 ]. On the other hand, studies on the status of the regulatory CK2β in cancer are rather scarce.…”

Section: Discussionsupporting

confidence: 92%

“…A preliminary report indicated that in human renal carcinoma the regulatory CK2β subunit increased even in higher amounts than the catalytic CK2α subunit [ 25 ]. In contrast, a recent report using a set of fifteen human renal cell carcinoma cell samples analyzed by western blot detected decreased CK2β levels in some of those samples [ 26 ]. However, the correlation between CK2β protein levels and the clinicopathological characteristics of the RCC remains unexplored.…”

Section: Introductionmentioning

confidence: 85%

See 1 more Smart Citation

Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival

Vilardell

Alcaraz

Sarró³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of renal cancer. STAT3 pathway is altered in these tumors and p-STAT3 Ser727 is an independent prognostic factor for ccRCC. Protein kinase CK2 is altered in different types of tumors and overexpression of CK2α is considered predictive of bad prognosis and metastatic risk. CK2 subunits analyses in ccRCC samples showed increased CK2α/α’ nuclear content in all cases, but decreased cytosolic CK2β (CK2βcyt) levels in the more advanced tumors. Stable downregulation of CK2β in renal proximal tubular (HK-2) and clear cell adenocarcinoma (786-O) cells triggered changes in E-cadherin, vimentin and Snail1 protein levels indicative of epithelial-to-mesenchymal transition (EMT), and increased HIF-α. Moreover, CK2β was required in order to observe STAT3 Ser727 phosphorylation in HK-2 but not in 786-O cells.We also observed that CK2β improved the prognostic value of p-STAT3 Ser727, as CK2βcyt>41 (median value) discriminates patients free of disease for a period of 10 years upon surgery, from those with CK2βcyt<41, when p-STAT3 Ser727levels are low.We conclude that CK2β down-regulation might represent a mechanism to support EMT and angiogenesis and that CK2βcyt levels are instrumental to refine prognosis of ccRCC patients with low p-STAT3 Ser727 levels.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 85%

Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival

Vilardell

Alcaraz

Sarró³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…In contrast, Roelants et al . find a decrease in all CK2 transcript levels of 1.5–16 times by RT-qPCR in clear cell renal carcinoma [ 79 ]. This observation on decreased transcript levels is in conflict with our analysis and that of Rabjerg et al .…”

Section: Results and Discussion: Ck2 Transcript Expression Levels Andmentioning

confidence: 99%

“…Despite finding decreased levels of all CK2 transcripts, Roelants et al . find increased CK2 activity, and increase in CK2α, CK2α’ and CK2β protein levels in renal cell carcinoma in 15 patients [ 79 ]. Similarly, other renal clear cell carcinoma studies show increase in CK2 activity [ 36 , 80 ].…”

Section: Results and Discussion: Ck2 Transcript Expression Levels Andmentioning

confidence: 99%

Cancer-type dependent expression of CK2 transcripts

2017

View full text Add to dashboard Cite

A multitude of proteins are aberrantly expressed in cancer cells, including the oncogenic serine-threonine kinase CK2. In a previous report, we found increases in CK2 transcript expression that could explain the increased CK2 protein levels found in tumors from lung and bronchus, prostate, breast, colon and rectum, ovarian and pancreatic cancers. We also found that, contrary to the current notions about CK2, some CK2 transcripts were downregulated in several cancers. Here, we investigate all other cancers using Oncomine to determine whether they also display significant CK2 transcript dysregulation. As anticipated from our previous analysis, we found cancers with all CK2 transcripts upregulated (e.g. cervical), and cancers where there was a combination of upregulation and/or downregulation of the CK2 transcripts (e.g. sarcoma). Unexpectedly, we found some cancers with significant downregulation of all CK2 transcripts (e.g. testicular cancer). We also found that, in some cases, CK2 transcript levels were already dysregulated in benign lesions (e.g. Barrett’s esophagus). We also found that CK2 transcript upregulation correlated with lower patient survival in most cases where data was significant. However, there were two cancer types, glioblastoma and renal cell carcinoma, where CK2 transcript upregulation correlated with higher survival. Overall, these data show that the expression levels of CK2 genes is highly variable in cancers and can lead to different patient outcomes.

show abstract

“…Thus, unbalanced expression of CK2 subunits is sufficient to drive epithelial-to-mesenchymal transition, a process involved in cancer invasion and metastasis. This dysregulated expression of CK2 subunits has been observed in breast cancer, renal cancer, lung adenocarcinoma, and glioblastoma [ 9 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells

Duchemin-Pelletier

Baulard

Spreux

et al. 2017

Cancers

Self Cite

View full text Add to dashboard Cite

The ubiquitous protein kinase CK2 has been demonstrated to be overexpressed in a number of human tumours. This enzyme is composed of two catalytic α or α’ subunits and a dimer of β regulatory subunits whose expression levels are probably implicated in CK2 regulation. Several recent papers reported that unbalanced expression of CK2 subunits is sufficient to drive epithelial to mesenchymal transition, a process involved in cancer invasion and metastasis. Herein, through transcriptomic and miRNA analysis together with comparison of cellular properties between wild type and CK2β-knock-down MCF10A cells, we show that down-regulation of CK2β subunit in mammary epithelial cells induces the acquisition of stem cell-like properties associated with perturbed polarity, CD44high/CD24low antigenic phenotype and the ability to grow under anchorage-independent conditions. These data demonstrate that a CK2β level establishes a critical cell fate threshold in the control of epithelial cell plasticity. Thus, this regulatory subunit functions as a nodal protein to maintain an epithelial phenotype and its depletion drives breast cell stemness.

show abstract

Dysregulated Expression of Protein Kinase CK2 in Renal Cancer

Cited by 13 publications

References 31 publications

Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival

Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival

Cancer-type dependent expression of CK2 transcripts

Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells

Contact Info

Product

Resources

About